Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

$More studies needed on bisphosphonates therapy and fracture risk$

More studies needed on bisphosphonates therapy and fracture risk

On October 13, the Food and Drug Administration published a warning to doctors and patients about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs called bisphosphonates. This warning was much awaited in the light of a report published in the American Journal of Bone and Mineral Research in September titled "Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research."

20 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Amgen will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

19 Oct 2010

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

The US Department of Defense (DOD) has awarded a $5 million grant to The Feinstein Institute for Medical Research and the University of Cincinnati to further develop a "lab-on-a-chip" device used for monitoring patients suffering from severe brain injury.

19 Oct 2010

Discovery of 4 new DNA 'hotspots' may aid in developing new therapies for psoriasis

Scientists at the University of Michigan Heath System and their collaborators have found four new DNA "hotspots" that may one day help guide new treatments for psoriasis, one of the most common autoimmune diseases in the country.

19 Oct 2010

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Findings from the PRECiSE 3 (P3) open label extension study for Cimzia, demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20. Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

19 Oct 2010

Discovery may aid in developing new psoriasis therapies

Scientists at the University of Michigan Heath System and their collaborators have found four new DNA “hotspots” that may one day help guide new treatments for psoriasis, one of the most common autoimmune diseases in the country.

18 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Studies and analyses of the Crohn's disease (CD) treatment Cimzia (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 – 20.

18 Oct 2010

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Biogen Idec and Elan Corporation, plc today announced data further supporting the potential clinical utility of an investigational assay that detects anti-JC virus (JCV) antibodies in human plasma or serum.

18 Oct 2010

Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

At the American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting today, researchers report progress on two top eye disease challenges treating advanced "dry" age-related macular degeneration, and preventing blindness in people with diabetes.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Questcor Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of epilepsy seen in infancy and early childhood.

15 Oct 2010

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Genentech, Inc., a member of the Roche Group, and Biogen Idec today announced 24-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate.

15 Oct 2010

UCB announces winners of 2010 UCB Crohn's and Me Scholarship Program

UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Crohn's and Me Scholarship Program for outstanding individuals affected by this condition. UCB has selected 31 winners to receive a scholarship worth up to $10,000 to help them seek personal growth through higher education.

15 Oct 2010

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Ligand Pharmaceuticals Incorporated today announced that its partner Pfizer, Inc. launched Viviant® (Bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. Under the brand name Conbriza®, the drug is also marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain.

14 Oct 2010

Four British Columbia students awarded 2010 UCBeyond Scholarship

For four students from British Columbia, their stories of perseverance in pursuing their hopes and dreams despite their illnesses is why they have been awarded $5,000 CAN each as the 2010 recipients of the UCBeyond Scholarship.

13 Oct 2010

MorphoSys and Proteros Biostructures receive research grant to develop new technology platform for structure-based engineering of antibodies

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Proteros Biostructures announced today that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural characterization of antibody-antigen-complexes.

12 Oct 2010

NIH awards La Jolla Institute $12.6M to develop San Diego's first Center for RNAi screening

The La Jolla Institute for Allergy & Immunology will develop San Diego's first Center for RNAi screening -- a breakthrough genomics technology that will further enhance San Diego's reputation as a national research leader and provide the local biomedical community ready access to the Nobel-Prize winning technology.

11 Oct 2010

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

More studies needed on bisphosphonates therapy and fracture risk

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

Discovery of 4 new DNA 'hotspots' may aid in developing new therapies for psoriasis

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Discovery may aid in developing new psoriasis therapies

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

UCB announces winners of 2010 UCB Crohn's and Me Scholarship Program

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Four British Columbia students awarded 2010 UCBeyond Scholarship

MorphoSys and Proteros Biostructures receive research grant to develop new technology platform for structure-based engineering of antibodies

NIH awards La Jolla Institute $12.6M to develop San Diego's first Center for RNAi screening

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in